Elitek (Sanofi-Synthelabo Inc)

Elitek (Sanofi-Synthelabo Inc) - General Information

Elitek (Sanofi-Synthelabo Inc) is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

Pharmacology of Elitek (Sanofi-Synthelabo Inc)

Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.

Additional information about Elitek (Sanofi-Synthelabo Inc)

Elitek (Sanofi-Synthelabo Inc) Indication: For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
Mechanism Of Action: Elitek (Sanofi-Synthelabo Inc) catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Rasburicase
Synonyms: Urate oxidase; Uricase
Drug Category: Antihyperuricemic Agents
Drug Type: Biotech; Approved

Other Brand Names containing Rasburicase: Elitek (Sanofi-Synthelabo Inc);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 18 hours
Dosage Forms of Elitek (Sanofi-Synthelabo Inc): Powder, for solution Intravenous
Chemical IUPAC Name: Aspergilus urate oxidase
Chemical Formula: C1521H2381N417O461S7
Rasburicase on Wikipedia: https://en.wikipedia.org/wiki/Rasburicase
Organisms Affected: Humans and other mammals